The three-year-old spinout from Zimmer Biomet has reached the end of its road. | The three-year-old spinout from Zimmer ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...

Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes. | A biotech incubator at the University of California, Berkeley is getting a ...

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...